Behcet Disease

Systemic vasculitis characterised by recurrent oral and genital ulceration, uveitis, and skin lesions. Involves both arteries and veins of all sizes. Most common along the 'Silk Road' from East Asia to the Mediterranean. Associated with HLA-B51.

Key Facts

Behcet disease is characterised by the triad of recurrent oral ulcers, genital ulcers, and uveitis HLA-B51 positive in 50-70% (especially in endemic regions); more common along the Silk Road (Turkey, Iran, Japan, China) Pathergy test: sterile needle prick → papule/pustule at 24-48 hours (positive in ~60% of Middle Eastern/Asian patients; rare in Western) Posterior uveitis/retinal vasculitis: the most serious ophthalmological manifestation; can cause blindness Venous thrombosis common (DVT, cerebral venous sinus thrombosis, Budd-Chiari); treat with immunosuppression NOT anticoagulation alone Arterial involvement: aneurysm formation (pulmonary artery aneurysms pathognomonic) Treatment: colchicine (oral ulcers, arthralgia), azathioprine (uveitis, mucocutaneous), anti-TNF (refractory), cyclophosphamide (neurological, major vessel) UK prevalence: rare (~1 per 100,000); higher in Turkish/Middle Eastern populations

Overview

Key Facts

Behcet disease is unique among vasculitides as it can affect both arteries and veins of all sizes. The variable-vessel vasculitis classification reflects this.

Epidemiology

  • Highest prevalence: Turkey (~400 per 100,000), Iran, Japan
  • UK prevalence: ~1 per 100,000; higher in immigrant populations from endemic areas
  • Peak onset: 20-40 years; M=F (but more severe in young males)

Pathophysiology

  • Neutrophilic vasculitis affecting all vessel sizes
  • Pathergy: exaggerated immune response to minor trauma (aberrant neutrophil function)
  • HLA-B51 associated; likely autoinflammatory rather than autoantibody-driven
  • IL-17 and TNF-α are key cytokines

Clinical Presentation

Oral Ulcers (>95%)

  • Recurrent (≥3 episodes/year)
  • Painful, round, well-circumscribed with erythematous halo
  • Affect lips, tongue, buccal mucosa, palate
  • Often the first and most common manifestation

Genital Ulcers (60-80%)

  • Painful; scrotum (males), vulva (females)
  • May scar (unlike oral ulcers)

Eyes (50-70%)

  • Posterior uveitis/panuveitis: most serious; risk of blindness
  • Anterior uveitis: hypopyon (pus layer in anterior chamber) – classic but uncommon
  • Retinal vasculitis: threatens vision

Skin (50-80%)

  • Erythema nodosum, papulopustular lesions, pseudofolliculitis
  • Pathergy positive

Vascular (25-30%)

  • Venous: DVT, SVT, cerebral venous sinus thrombosis, Budd-Chiari
  • Arterial: aneurysms (especially pulmonary artery – pathognomonic)

Neurological (Neuro-Behcet, 5-10%)

  • Meningoencephalitis, brainstem syndrome
  • Cerebral venous sinus thrombosis
  • Progressive neurological disability

Other

  • Arthritis: oligoarticular, non-erosive
  • GI: ulceration (ileocaecal, mimics Crohn's)

Red Flags

  • Posterior uveitis → urgent ophthalmology + immunosuppression
  • Haemoptysis → pulmonary artery aneurysm → life-threatening
  • Headache/neurological signs → neuro-Behcet or CVST

Differential Diagnosis

DiagnosisKey FeaturesInvestigation
SLEOral ulcers, arthritis, ANA/dsDNA positiveImmunology
Crohn diseaseOral ulcers, GI ulceration, perianal diseaseColonoscopy
Reactive arthritisOral ulcers, urethritis, arthritisClinical
HSVOral/genital ulcers, vesicularViral swab/PCR
SyphilisPainless chancre, rash, FTA-AbsSyphilis serology

Diagnosis / Investigation

Diagnosis is Clinical (ISG Criteria)

  • Recurrent oral ulceration (≥3 episodes in 12 months) PLUS ≥2 of:
    • Recurrent genital ulceration
    • Eye lesions (uveitis, retinal vasculitis)
    • Skin lesions (erythema nodosum, pseudofolliculitis)
    • Positive pathergy test

Bloods

  • HLA-B51: supportive (not diagnostic)
  • CRP/ESR: elevated during flares
  • No specific autoantibody (ANCA negative, ANA negative)

Imaging

  • CT/MR angiography: pulmonary artery aneurysms, venous thrombosis
  • MRI brain: neuro-Behcet (brainstem lesions)
  • MR venography: cerebral venous sinus thrombosis

Other

  • Pathergy test: read at 24-48 hours; sterile pustule formation (positive)
  • OCT/fluorescein angiography: retinal vasculitis assessment

Management

Mucocutaneous (Oral/Genital Ulcers)

  • Colchicine 500mcg BD: first-line for oral ulcers and arthralgia
  • Topical steroids (triamcinolone oral paste)
  • Azathioprine: for recurrent/severe mucocutaneous disease
  • Apremilast 30mg BD: NICE approved for refractory oral ulcers

Uveitis

  • Azathioprine: first-line for posterior uveitis/retinal vasculitis
  • Anti-TNF (infliximab, adalimumab): for sight-threatening disease or refractory
  • Ciclosporin: alternative
  • Interferon-α: used in specialist centres
  • Topical steroids + mydriatics: for anterior uveitis

Vascular

  • Immunosuppression is primary treatment for thrombosis (NOT anticoagulation alone – risk of aneurysm rupture)
  • Azathioprine, cyclophosphamide, or anti-TNF
  • Anticoagulation: controversial; some use cautiously in combination with immunosuppression

Neuro-Behcet

  • IV methylprednisolone + cyclophosphamide or infliximab
  • Azathioprine maintenance

Pulmonary Artery Aneurysm

  • Cyclophosphamide + corticosteroids: EMERGENCY
  • Embolisation if life-threatening haemoptysis
  • AVOID anticoagulation (aneurysm rupture risk)

Referral

  • Suspected Behcet → rheumatology (specialist Behcet centre if available)
  • Posterior uveitis → ophthalmology
  • Neuro-Behcet → neurology + rheumatology

Prognosis

  • Mortality: low (<5% at 10 years) with modern treatment
  • Visual loss: reduced to <10% with immunosuppression (vs >25% historically)
  • Pulmonary artery aneurysm: high mortality without treatment
  • Neuro-Behcet: can cause significant disability; progressive form has worse prognosis
  • Disease activity often diminishes with age
  • Young males have the most severe disease and worst prognosis

Other Relevant Information

ISG Diagnostic Criteria

Recurrent oral ulceration (≥3/year) PLUS ≥2 of:

  1. Recurrent genital ulceration
  2. Eye lesions
  3. Skin lesions
  4. Positive pathergy test

Behcet Disease UK Specialist Centres

  • London (Royal London Hospital)
  • Birmingham
  • Liverpool
  • Leeds